Mechanism of solvent-mediated polymorphic transformation to prepare axitinib form XLI controlled by water activity

Tong Li,Jin Zhang,Maolin Li,Haibin Qu,Songgu Wu,Junbo Gong
DOI: https://doi.org/10.1039/d4ce00863d
IF: 3.756
2024-10-17
CrystEngComm
Abstract:Axitinib (AXI) is widely used in the treatment of renal cancer. Due to its molecule structure containing multiple hydrogen bond acceptors and donors, AXI has been reported five solvent-free polymorphs and over 60 solvates. Among these, form XLI is utilized in clinical treatments due to its stability and efficacy. However, obtaining form XLI through direct solution crystallization is challenging. In this study, a new strategy for the preparation of form XLI was developed, enabling the acquisition of form XLI crystals within a minimum 140 min via solvent-mediated polymorphic transformation (SMPT) using AXI SDMF solvate as the precursor. Powder X-ray diffraction (PXRD) and Raman spectroscopy were used to monitor the SMPT process, revealing that the formation of AXI form XLI strongly depended on the water activity of the solvent system. The dissolution of form IV and the nucleation of form XLI were identified as the rate-limiting steps. Online infrared spectroscopy demonstrated that the solvent environment significantly influenced the polymorphic transformation by affecting the molecular conformation and assembly of AXI in solution. Additionally, the effects of temperature, solid content, and solvent composition on the SMPT process were investigated to enhance control over the transformation. Our study provides an efficient method for the preparing of AXI form XLI.
chemistry, multidisciplinary,crystallography
What problem does this paper attempt to address?